These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 3649341)

  • 41. [Validation of the virus inactivation capacity of a procedure of human plasma albumin purification by chromatography].
    Stoltz JF; Geschier C; Rivat C; Sertillanges P; Grandgeorges M; Liautaud J; Regnault V; Dumont L
    Ann Pharm Fr; 1993; 51(2):78-93. PubMed ID: 8250488
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Heat inactivation of human immunodeficiency virus in solutions of antithrombin III.
    Einarsson M; Perenius L; McDougal JS; Cort S
    Transfusion; 1989 Feb; 29(2):148-52. PubMed ID: 2919425
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Inactivation of human immunodeficiency virus type I in human milk: effects of intrinsic factors in human milk and of pasteurization.
    Orloff SL; Wallingford JC; McDougal JS
    J Hum Lact; 1993 Mar; 9(1):13-7. PubMed ID: 8489717
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Inactivation of viruses by pasteurization at 60 °C for 10 h with and without 40% glucose as stabilizer during a new manufacturing process of α2-Macroglobulin from Cohn Fraction IV.
    Huangfu C; Ma Y; Jia J; Lv M; Zhu F; Ma X; Zhao X; Zhang J
    Biologicals; 2017 Mar; 46():139-142. PubMed ID: 28215695
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Virus reduction in the preparation of intravenous immune globulin: in vitro experiments.
    Chandra S; Cavanaugh JE; Lin CM; Pierre-Jerome C; Yerram N; Weeks R; Flanigan E; Feldman F
    Transfusion; 1999 Mar; 39(3):249-57. PubMed ID: 10204586
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Human intravenous immunoglobulin preparation and virus inactivation by pasteurization and solvent detergent treatment.
    Chang CE; Eo HG; Lee YS; Chung SK; Shin JS; Lah YK; Park CW; Jung JT; Huh JW; Lee SM
    Prep Biochem Biotechnol; 2000 Aug; 30(3):177-97. PubMed ID: 10919559
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Evaluation of viral safety of a high-purity human factor VIII concentrate submitted to 2 specific virus inactivation treatments (FANDHI)].
    Ristol P; Gensana M; Fernández J; Massot M; Biescas H; Darling A; Jorquera JI; Vericat F
    Sangre (Barc); 1996 Apr; 41(2):131-6. PubMed ID: 9045353
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Validation of removal of human retroviruses.
    Marcus-Sekura CJ
    Dev Biol Stand; 1991; 75():133-43. PubMed ID: 1794615
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Heat inactivation of human immunodeficiency virus in lyophilized anti-inhibitor coagulant complex (Autoplex).
    Piszkiewicz D; Thomas W; Lieu M; Cabradilla CD; Andrews J; Kim J; Bourret E; McDougal JS; Cort SP
    Thromb Res; 1986 Dec; 44(5):701-7. PubMed ID: 3492776
    [No Abstract]   [Full Text] [Related]  

  • 50. Prevention of iatrogenic transmission of B19 infection: different approaches to detect, remove or inactivate virus contamination.
    Bonvicini F; Gallinella G; Gentilomi GA; Ambretti S; Musiani M; Zerbini M
    Clin Lab; 2006; 52(5-6):263-8. PubMed ID: 16812953
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Safety of an intravenous immunoglobulin preparation: lack of seroconversion for human immunodeficiency virus antibodies.
    Lee ML; Kingdon HS; Hooper J; Courter SG; Holst SL; Piszkiewicz D
    Clin Ther; 1987; 9(3):300-3. PubMed ID: 3111704
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Evolution of approaches to viral safety issues for biological products.
    Lubiniecki AS
    PDA J Pharm Sci Technol; 2011; 65(6):547-56. PubMed ID: 22294576
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Inactivation of human immunodeficiency virus in serum specimens as a safety measure for diagnostic immunoassays.
    Ukkonen P; Korpela J; Suni J; Hedman K
    Eur J Clin Microbiol Infect Dis; 1988 Aug; 7(4):518-23. PubMed ID: 3141160
    [TBL] [Abstract][Full Text] [Related]  

  • 54. At what stage should virus inactivation be carried out?
    Dorner F; Barrett PN; Eibl J
    Dev Biol Stand; 1993; 81():137-43. PubMed ID: 8174796
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effect of viral nucleic acid testing on contamination frequency of manufacturing plasma pools.
    Nübling CM; Unkelbach U; Chudy M; Seitz R
    Transfusion; 2008 May; 48(5):822-6. PubMed ID: 18208414
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Ensuring the biologic safety of plasma-derived therapeutic proteins: detection, inactivation, and removal of pathogens.
    Cai K; Gierman TM; Hotta J; Stenland CJ; Lee DC; Pifat DY; Petteway SR
    BioDrugs; 2005; 19(2):79-96. PubMed ID: 15807628
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Inactivation of human immunodeficiency virus during human growth hormone production.
    Dormont D; Vaslin B; Dubeaux D; Boussin F; Maillard F; Deslys JP
    Arch Virol; 1988; 100(1-2):135-8. PubMed ID: 3390001
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Inactivation of hepatitis A virus by heat treatment in aqueous solution.
    Murphy P; Nowak T; Lemon SM; Hilfenhaus J
    J Med Virol; 1993 Sep; 41(1):61-4. PubMed ID: 8228940
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Survey of non-U.S. hemophilia treatment centers for HIV seroconversions following therapy with heat-treated factor concentrates.
    Centers for Disease Control (CDC)
    MMWR Morb Mortal Wkly Rep; 1987 Mar; 36(9):121-4. PubMed ID: 3102937
    [No Abstract]   [Full Text] [Related]  

  • 60. Validation of virus inactivation by heat treatment in the manufacture of diaspirin crosslinked hemoglobin.
    Farmer M; Ebeling A; Marshall T; Hauck W; Sun CS; White E; Long Z
    Biomater Artif Cells Immobilization Biotechnol; 1992; 20(2-4):429-33. PubMed ID: 1327242
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.